KSI-101 - Business-News-Today.com

Business-News-Today.com

Business news, market intelligence, and global industry analysis.

Business-News-Today.com

The Latest

Willow Lane Acquisition enters public markets with $10 per unit IPO, betting on selective dealmaking

Galaxy Surfactants (NSE: GALAXYSURF) Q3 FY26 results signal portfolio resilience as specialty growth offsets global surfactant pressures

Natural Capsules (NSE: NATCAPSUQ) Q3 FY26 results signal operational recovery after regulatory shock, but fermentation execution risk still looms

Why Eli Lilly and Company is stockpiling a weight loss pill before the FDA has even said yes

Read More

5 minute read

Pharma Industry News

Nasdaq: KOD — Is Kodiak Sciences’ KSI-101 finally turning Wall Street bullish on ocular inflammation?

Explore how Kodiak Sciences’ KSI‑101 is reshaping the retinal‑disease treatment landscape and why JPMorgan just upgraded the stock—read more now!

byPallavi Madhiraju

October 25, 2025

web analytics